Chemomab Therapeutics Ltd.
CMMB
$1.74
-$0.03-1.70%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | 88.25% | -97.10% |
| Total Depreciation and Amortization | -- | -- | -- | -75.38% | 52.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -88.06% | -1.02% |
| Change in Net Operating Assets | -- | -- | -- | -138.99% | 353.22% |
| Cash from Operations | -- | -- | -- | 85.48% | -61.20% |
| Capital Expenditure | -- | -- | -- | 100.00% | 78.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -92.67% | 172.64% |
| Cash from Investing | -- | -- | -- | -92.67% | 173.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 24.01% | -96.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -696.08% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 324.90% | -106.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 108.81% | 115.64% |